UCL's Freeline Therapeutics has priced its shares at $18 to raise nearly $159m through an IPO on the Nasdaq Global Select Market.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Humana-backed primary care network Oak Street Health is raising $328m in an offering in which it priced its shares above an expanded range.

Novartis Venture Fund has helped seed a T-cell drug developer founded from Seattle Children's Hospital, Benaroya Research Institute and MIGAL Galilee.

Lepu Medical's immuno-oncology spinoff secured $186m in a round co-led by Ping An Capital and the Sunshine Insurance-backed Riverhead Capital.

The T-cell drug developer has launched with $20m from a seed round co-led by corporate venturing unit Novartis Venture Fund.

NetScientific is poised to acquire EMV Capital in an all-share deal after appointing the latter's managing director as its chief executive in May.

Sinpoharm-backed joint venture Sinopharm-CICC was among the investors in a $43.2m round that boosted the antimicrobial drug developer's total funding to near $150m.

The mental well-being and recruitment services provider has launched an investment vehicle that will provide up to $950,000 per deal.

The UK regional tech transfer alliance's Seed Investment Fund expects to close its first investments in coming months, targeting sectors including healthcare and data.